Ferguson PLC Results for the 3 months ended 30 April 2019

Ferguson PLC

CONTINUED GROWTH, RE-AFFIRMING GUIDANCE, $500 MILLION SHARE BUY BACK

Ongoing businesses1US$ millionsQ3 2019Q3 2018 Change
Revenue5,2744,968+6.2%
Trading profit2359351+2.3%
Net debt to EBITDA 0.9x0.9x3

 

Third quarter highlights

−          Ongoing revenue growth of 6.2%, including 8.4% in the USA.

−          Solid gross margins, slightly ahead of last year.

−          Good cost control, underlying operating costs lower than in Q2.

−          Ongoing trading profit of $359 million was $8 million ahead of last year.

−          Strong operating cash generation of $632 million in the quarter with net debt to EBITDA of 0.9x.

−          Share buy back of $500 million announced today.

 

John Martin, Group Chief Executive, commented:

“The Group continued to grow in Q3 with revenue 6.2% ahead. We also continued to successfully grow our gross margins and have improved our underlying cost base over the last two quarters.

“We are confident that Ferguson will continue to make progress as we remain firmly focused on delivering superior customer service. We expect to generate ongoing Group trading profit in the year ended 31 July 2019 in line with current analysts’ consensus forecasts.4

“Cash generation continued to be excellent and our balance sheet remains strong. We will continue to invest organically in our businesses supplemented by bolt-on acquisitions in our core operations. Given our strong financial position, and in line with our capital allocation policy, we are initiating a $500 million share buy back programme which we expect to complete over the next 12 months.”

Share on:

Latest Company News

Thermostatic showers are becoming the default choice

Thermostatic showers solve a basic problem most homes still have, unstable water temperature, with a simple, lasting fix.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in UK manufacturing could reshape the narrative

UK manufacturing moves back into growth as easing costs and rising orders open up early-stage opportunities for investors.

Ilika targets neuromodulation market with medical battery offering

Ilika is stepping directly into the medical-device market with its solid-state microbattery platform now featured at NANS 2026.

Cerillion CEO Louis Hall on Record Annual Results and Growth Outlook (LON:CER)

Cerillion plc CEO Louis Hall discusses record annual results, a stronger order book, and growing market acceptance following two significant contract wins.

Controlled burning gains traction as a land management tool with ecological upside

Prescribed burning is becoming a standard tool for protecting forestry assets and restoring high-value wildlife habitat across the US Southeast.

    Search

    Search